Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21119070 | 0.86 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL6918898 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL1306542 | 0.76 | CA1 (0.64) | ALDH1A1MEN1KMT2ARAB9AGAA | |
| SCHEMBL6045162 | 0.74 | MEN1 (0.58) | MEN1KMT2ARAB9APOLBNPC1 | |
| SCHEMBL30942651 | 0.73 | POLB (0.75) | ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL10491219 | 0.73 | POLB (0.75) | ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL5436492 | 0.71 | POLB (0.77) | ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL6307108 | 0.71 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL15094713 | 0.71 | L3MBTL1 (0.64) | ALDH1A1MEN1KMT2ARAB9APOLB | |
| SCHEMBL34461586 | 0.71 | LMNA (0.55) | ALDH1A1MEN1KMT2ARAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-9234230-B2 | Screening method and compounds for modulating telomerase activity | THE WISTAR INSTITUTE (US) | 2016-01-12 | — | — | US | disclosed |
| US-8377992-B2 | TRBD-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | THE WISTAR INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100160260-A1 | TRBD-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | THE WISTAR INSTITUTE | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | TERT, TERB1, TERF2 | ALDH1A1 3360/4885MEN1 3807/4885KMT2A 2921/4885 |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | TERT, TERB1, TERF2 | ALDH1A1 3360/4885MEN1 3807/4885KMT2A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.